MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
MacroGenics (MGNX) PT Raised to $40 at SunTrust Robinson Humphrey
February 6, 2019 1:30 PM ESTSunTrust Robinson Humphrey analyst Peter Lawson raised the price target on MacroGenics (NASDAQ: MGNX) to $40.00 (from $28.00) while maintaining a Buy rating.
... MoreMacrogenics (MGNX) Adds to Gains, Up 140%
February 6, 2019 9:06 AM ESTMacrogenics (NASDAQ: MGNX) Adds to Gains, Up 140%
... MoreMacrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISI
February 6, 2019 8:47 AM ESTEvercore ISI analyst Umer Raffat said a $2 billion+ valuation for Macrogenics (NASDAQ: MGNX) is 'very likely' as SOPHIA hits.
Macrogenics (MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
February 6, 2019 7:55 AM ESTMacrogenics (NASDAQ: MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
... More